Enovis (NYSE:ENOV) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker6Good day, and welcome to the Enovis fourth quarter 2025 earnings conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press Star, then 1 on your touchtone phone. To withdraw your question, please press Star then 2 ...

Integra LifeSciences (NasdaqGS:IART) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker5Good day, and welcome to the Integra LifeSciences fourth quarter 2025 financial results. At this time, all participants are in listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question, please press star 1. To remove yourself from the queue, press star 1 1 again. This call may be recorded. I would now like to turn the call over to Chris Ward, Senior Director ...

新京报贝壳财经讯2月26日，安杰思发布业绩快报，2025年度公司实现营业总收入5.97亿元，同比下降 6.19%；归母净利润2.23亿元，同比下降24.06%。报告期内，公司所处的医疗器械行业因受到国内医保 集中带量采购和海外关税政策等行业因素的影响，公司主营业务所处的内镜微创诊疗领域受到行业竞争 加具的影响，致使公司2025年全年业绩阶段性承压。 ...

Core Viewpoint - Sanofi Bio is transforming into a "diabetes digital management expert" by leveraging its "Aikan Health" app as a user entry point, enhancing user engagement and retention, and building a valuable user base [1] Group 1: Business Strategy - The company aims to create a personalized and interactive health management ecosystem by integrating CGM data with AI technology and its existing multi-device layout, which includes blood glucose, uric acid, blood lipids, glycosylated hemoglobin, and blood pressure [1] - The commercialization of this ecosystem will depend on user base accumulation, cultivation of payment habits, deepening ecological cooperation, and improving service systems, indicating a long-term strategic layout [1] Group 2: Market Exploration - The company will explore and tap into different market demands and user habits during its development process, indicating a flexible approach to market needs [1] - Continuous exploration of the "biosensor + artificial intelligence + healthcare" new model will be pursued to promote a closed-loop management system for diabetes [1]

Teleflex (NYSE:TFX) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsBradley Bowers - VP of Equity ResearchJayson Bedford - Managing Director of Equity ResearchJohn Deren - EVP and CFOLawrence Keusch - Vice President of Investor Relations and Strategy DevelopmentStuart Randle - Interim President and CEOTravis Steed - Managing Director of Medical Technology Equity ResearchConference Call ParticipantsLarry Biegelsen - Senior Medical Device Equity Research AnalystMatthew O'Brien - Managi ...

Teleflex (NYSE:TFX) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsBradley Bowers - VP of Equity ResearchJayson Bedford - Managing Director of Equity ResearchJohn Deren - EVP and CFOLawrence Keusch - Vice President of Investor Relations and Strategy DevelopmentStuart Randle - Interim President and CEOTravis Steed - Managing Director of Medical Technology Equity ResearchConference Call ParticipantsLarry Biegelsen - Senior Medical Device Equity Research AnalystMatthew O'Brien - Managi ...

NovoCure (NasdaqGS:NVCR) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker6Thank you for standing by. Welcome to the Novocure Fourth Quarter 2025 Earnings Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you'll need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press sta ...

证券日报网讯 2月26日，迈得医疗发布公告称，2025年公司实现营业收入44741.90万元，同比上升 62.79%；实现归属于母公司所有者的净利润6525.99万元，实现扭亏为盈。 （文章来源：证券日报） ...

报告期内，公司面对行业众多挑战，始终专注于内镜微创诊疗器械与高端诊断设备领域的研发与自主创 新，进一步丰富内镜微创诊疗器械产品覆盖面，持续加大自动化产线投入，保持毛利率相对稳定，提升 公司内镜微创诊疗器械产品市场竞争力。公司坚持执行全球化的发展战略，加大荷兰子公司的本土化运 营以及泰国生产基地项目建设，持续深化渠道客户管理和新兴市场开拓。报告期内公司加大对杭安医学 多条研发管线的投入，深化诊疗设备和医疗器械的双驱动发展战略布局，为公司2026年的业务增长奠定 良好基础。综上所述，报告期内公司各项研发开支，生产管线更新、国内外市场运营建设费用等均保持 较高投入，因此对当期利润产生一定的影响。 报告期内，公司所处的医疗器械行业因受到国内医保集中带量采购和海外关税政策等行业因素的影响， 公司主营业务所处的内镜微创诊疗领域受到行业竞争加具的影响，致使公司2025年全年业绩阶段性承 压。 格隆汇2月26日丨安杰思(688581.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入5.97亿 元，较上年同期下降6.19%；归属于母公司所有者的净利润2.23亿元，较上年同期下降24.06%；归属于 母公司所有者的扣 ...

格隆汇2月26日｜安杰思公告，公司2025年实现营业总收入59,720.71万元，较上年同期下降6.19%；归 属于母公司所有者的净利润22,281.69万元，较上年同期下降24.06%；归属于母公司所有者的扣除非经 常性损益的净利润19,141.86万元,较上年同期下降29.81%。报告期内，公司所处的医疗器械行业因受到 国内医保集中带量采购和海外关税政策等行业因素的影响，公司主营业务所处的内镜微创诊疗领域受到 行业竞争加具的影响，致使公司2025年全年业绩阶段性承压。 ...